Growth hormone (GH) is the most frequently used treatment in children with idiopathic short stature (ISS). Aromatase inhibitor (AI) therapy is still in an experimental state, and both fi nal height (FH) and long-term effi cacy data in ISS have not been published. We present a 14.5-year-old boy with ISS and a height of 142.7 cm [standard deviation score (SDS) -2.79]. Based on the baseline bone age (BA) of 13.5 -14 years, his predicted adult height (PAH) by Bayley/Pinneau was 154 cm (SDS -3.77) -158.2 (SDS -3.15). After a 5-year letrozole monotherapy, FH was 169 cm (SDS -1.57) showing a height difference between PAH and FH from 10.8 to 15 cm. No permanent side effects of the medication have been observed. Both a transient occurrence and a spontaneous recovery of decreased bone mineral apparent density were seen, verifi ed by dual-energy X-ray absorptiometry. Spinal magnetic resonance imaging revealed no vertebral abnormalities. AI therapy might be an effective and low-cost alternative to the use of GH. Further controlled trials should prove effi cacy and safety of long-term AI therapy in boys with ISS.
Introduction
The diagnosis of idiopathic short stature (ISS) requires an individual height of at least -2 standard deviation score (SDS) below the population mean for age and sex, and the absence of growth-related underlying diseases, such as endocrine disorders, malnutrition, chronic systemic diseases, or genetic defects (i.e., haploinsuffi ciency of the short stature homeobox-containing gene SHOX) (1) . Concomitant counseling of children with ISS is recommended if they suffer from stigmatization, social isolation, chronic psychosocial stress, and their restricted quality of life (2) . The importance of impairments related to short stature later in life is supported by a population-based study investigating the association between height and the risk of suicide in more than one million Swedish men. It could be shown that an increase in height of 5 cm was associated with a 9 % decrease in suicide risk (3) . Although psychosocial effects of short stature do not generally result in clinically significant problems of psychosocial adaptation, some patients suffer from it and consult frequently pediatric endocrinologists (2) . Growth hormone (GH) is the most frequently used medical treatment in children with ISS, which was approved in the United States by the Food and Drug Administration (FDA) in 2003 (1, 2) , but the European Medicines Agency (EMEA) has not been given an approval for GH in ISS so far. The alternative aromatase inhibitor (AI) therapy, which has been shown to be effective in increasing predicted adult height (PAH) in children with ISS, is still at the experimental stage (4) . However, the costs of treatment are considerably lower administering an AI than GH. The treatment with GH in children with ISS has resulted in a mean increase in adult height of 3.5 -7.5 cm during a 4-to 10-year period of treatment (1) . Previous treatment with the AI letrozole for 2 years has led to a PAH increase of 5.9 cm in boys with ISS (4) . The main reasons for describing the case of a boy with ISS are a safe long-term letrozole monotherapy over 5 years resulting in a 10.8-to 15-cm height difference between PAH and fi nal height (FH) and the reversibility of decreased bone mineral apparent density (BMAD) 3 years after fi nishing the letrozole therapy.
Patient report
The 14.5-year-old boy was referred to pediatric endocrine evaluation because of severe short stature. There was no family history of endocrine or bone diseases. The mother was measured at 155 cm (SDS -1.87), and the father ' s height was 167 cm (SDS -2.01). The boy was born after 40 weeks of normal pregnancy and delivery to healthy, non-consanguineous parents with a birth weight of 3315 g (SDS -0.58) and a length of 49 cm (SDS -0.92). At initial presentation, the patient had a height of 142.7 cm ( -2.79 SDS) and a weight of 38.7 kg, for a body mass index of 19 kg/m 2 (50th percentile for age and gender). His genetic target height by Tanner (5) was 167.5 cm (SDS -1.79), calculated by the equation: (father ' s height + mother ' s height)/2 ± 6.5 cm. He was proportionate, had no dysmorphic features, and was pubertal, with Tanner stage 2 as to pubic hair and genital development. His testicular volume was 5 mL. Estimated bone age (BA) was 13.5 -14 years by Greulich/Pyle method. Therefore, PAH by Bayley/Pinneau method (6) was154 cm (SDS -3.77) to 158.2 cm (SDS -3.15). Laboratory analyses including hepatic, renal, and endocrine function, sweat test, and celiac disease markers were normal.
Results

Growth
Treatment with the AI letrozole (Femara, Novartis AG, Switzerland) at a dose of 2.5 mg daily was administered for 5 years. Based on the baseline BA of 13.5 -14 years, the difference between PAH of 154 (SDS -3.77) to 158.2 (SDS -3.15) cm at the beginning and FH of 169 cm (SDS -1.57) at the end of the letrozole therapy was10.8 -15 cm. FH was defi ned as height at an age ≥ 22 years or height velocity ≤ 0.5 cm in the foregoing year. The height velocity during the 5-year follow-up period is shown in Figure 1 . The patient did not report any 
Laboratory determinations
The patient was particularly monitored for endocrine, hepatic, and renal functions and showed no signifi cant modifi cation (Table 1 ) .
Radiological fi ndings
Repeated hand X-rays were performed and revealed an estimated BA by Greulich/Pyle method of 13.5 -14 years at a chronological age of 14.5 years and a BA of 16 years at the end of the 5-year treatment period when the patient was 19.5 years old (see Figure 1 ). Hand bones showed no signs of demineralization or fractures. BA determinations were performed by two independent pediatric radiologists (O.M-E, M.U.). In addition, spinal magnetic resonance imaging (MRI) of the patient was performed using a 1.5-Tesla Imager (MR-Avanto, Siemens Medical Systems, Erlangen, Germany) in two steps. First, the imaging protocol of the cervical and upper thoracic spine. Second, the imaging protocol of the lower thoracic and lumbosacral spine. The composed sequences with 11 sagittal slices were performed with T1-weighted (fi eld of view (FOV) 679 × 379 mm, slice thickness 3 mm, gap 10 % = 0.3 mm, acquisition matrix 416 × 746 mm) and T2-weighted (FOV 681 × 379 mm, slice thickness 3 mm, gap 10 % = 0.3 mm, acquisition matrix 486 × 872 mm) images. All protocols consisted of turbo-spin echo sequences for the assessment of vertebral anatomy, endplate abnormalities, and intervertebral disk. The MRI images were visually analyzed for vertebral anatomy and shape, endplate changes, disk height and water content, and muscle status of the back by a radiologist (OM-E). Measurements of vertebral body dimensions and assessments of the shape of each vertebral body were performed with a digital caliper in the radiologic workstation. Our patient showed no abnormalities in spinal MRI (Figure 2 ). The shapes of all vertebral bodies were classifi ed as normal using the classifi cation for pediatric vertebral body morphology (7) .
Bone mineral apparent density (BMAD )
After discontinuation of letrozole treatment, examination of BMAD (8) with dual-energy X-ray absorptiometry (DXA) scanning (Lunar Prodigy Advance, GE Lunar Corp, Madison, WI, USA) was carried out investigating the 2nd-4th vertebrae of the lumbar spine and the femoral neck. BMAD of the spine was 0.144 g/cm 3 (T-score: -0.84) and of the femoral neck 0.146 g/cm 3 (T-score: -0.89). After a 3-year ambulatory care without any medication, the bone mineral content values returned to normal, and BMAD of the spine was 0.168 g/cm 3 (T-score: 0.37) and of the femoral neck 0.174 g/cm 3 (T-score: 0.11).
Discussion
Based on the BA of 13.5 -14 years, the present casuistics describes a height difference from 10.8 to15 cm between PAH and an FH after a 5-year AI monotherapy with letrozole in a pubertal boy with ISS. To date, AI therapy is still at the experimental stage (4) , and no long-term effi cacy and adult height data in males with ISS have been published. An improvement in PAH by 5.9 cm during a 2-year treatment with letrozole (2.5 mg, once daily) in 31 boys with ISS, aged 9.0 -14.5 years, could be shown in a placebo-controlled Finnish study (9) . Therefore, our case report might be a helpful hint indicating the possibility of increasing FH in males with ISS by longterm AI therapy.
In comparison with GH monotherapy up to 10 years, AI monotherapy might not only be equally effective in increasing PAH and adult height in boys with ISS but also a lowcost alternative (1, 4, 9) . Future well-controlled studies in children with ISS should involve long-term AI treatment with regard to adult height outcome and safety. In terms of AI therapy, some potential safety concerns exist. Highdensity lipoprotein cholesterol could decrease, but suffi cient data are still lacking regarding the infl uence of aromatase inhibition on spermatogenesis, cognitive function, vascular wall function, and prostate growth (4) . Short-term AI therapy in ISS has proved to be well tolerated, but the number of patients who are treated within clinical trials is small (1, 4, 9) . In patients who may receive long-term AI therapy, bone health is of particular interest. AI treatment prevents biosynthesis of estrogen, thereby slowing its effi cacy on skeletal maturation, especially epiphyseal closure and bone mineralization (1, 4) . Transiently reduced BMAD after a 5-year letrozole therapy in our adolescent boy may support the importance of monitoring bone health during AI therapy. But the spontaneous recovery also shows that no permanent harm is to be expected. Hero et al. reported mild vertebral body deformities in the thoracic spine (MRI) in 5 of 11 boys with ISS (mean age 10.7 years) who received letrozole for 2 years during prepuberty or early puberty (10) . The authors discussed the possibility that the use of AI treatment during prepuberty may be associated with an increased risk of vertebral deformities. Although our patient was during midpuberty and 4 years older than the boys with ISS described by Hero et al., we carefully assessed his vertebral morphology by spine MR imaging, but no abnormalities could be found. In adolescent males with GH defi ciency, an increase in adult height potential was seen by adding an AI to GH therapy. Normal pubertal progression and bone health were found after 2 -3 years with this combination therapy (11) . Another randomized, placebo-controlled study could show that boys with constitutional delay of puberty who received the AI letrozole in combination with low-dose testosterone reached a higher mean near-fi nal height than boys on testosterone monotherapy (12) . Considering the positive effects of GH on BMD, the use of GH, together with an AI, might also be a treatment option in adolescents with ISS.
In conclusion, this case involves a 14.5-year-old boy with ISS who achieved a height increase between PAH and FH from 10.8 to 15 cm during a 5-year AI therapy. In addition, the boy showed both a transient occurrence and a spontaneous recovery of decreased BMAD after long-term AI therapy, verifi ed by DXA. MRI revealed no vertebral morphology abnormalities. Any other measures regarding health and safety monitoring showed no pathology. Therefore, AI therapy might be an effective and low-cost alternative to the use of GH. However, these fi ndings deserve further attention, and controlled long-term studies are necessary to prove safety and effi cacy of AI treatment in males with ISS.
